|
1
|
Lv H, Yan M and Jiang Z: Recent advances
in the treatment of hormone receptor-positive/human epidermal
growth factor 2-positive advanced breast cancer. Ther Adv Med
Oncol. 13:175883592110133262021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parise CA and Caggiano V: Differences in
clinicopatholgic characteristics and risk of mortality between the
triple positive and ER+/PR+/HER2-breast cancer subtypes. Cancer
Causes Control. 30:417–424. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vici P, Pizzuti L, Natoli C, Gamucci T, Di
Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, et
al: Triple positive breast cancer: A distinct subtype? Cancer Treat
Rev. 41:69–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tran B and Bedard PL: Luminal-B breast
cancer and novel therapeutic targets. Breast Cancer Res.
13:2212011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Knutson TP and Lange CA: Tracking
progesterone receptor-mediated actions in breast cancer. Pharmacol
Ther. 142:114–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Untch M, Gelber RD, Jackisch C, Procter M,
Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, et
al: Estimating the magnitude of trastuzumab effects within patient
subgroups in the HERA trial. Ann Oncol. 19:1090–1096. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schettini F, Buono G, Cardalesi C,
Desideri I, De Placido S and Del Mastro L: Hormone receptor/human
epidermal growth factor receptor 2-positive breast cancer: Where we
are now and where we are going. Cancer Treat Rev. 46:20–26. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dahabreh IJ, Linardou H, Siannis F,
Fountzilas G and Murray S: Trastuzumab in the adjuvant treatment of
early-stage breast cancer: A systematic review and meta-analysis of
randomized controlled trials. Oncologist. 13:620–630. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilken JA and Maihle NJ: Primary
trastuzumab resistance: New tricks for an old drug. Ann N Y Acad
Sci. 1210:53–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zazo S, González-Alonso P, Martín-Aparicio
E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P,
Lluch A, et al: Generation, characterization, and maintenance of
trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer
Res. 6:2661–2678. 2016.PubMed/NCBI
|
|
12
|
Lindet C, Révillion F, Lhotellier V,
Hornez L, Peyrat JP and Bonneterre J: Relationships between
progesterone receptor isoforms and the HER/ErbB receptors and
ligands network in 299 primary breast cancers. Int J Biol Markers.
27:e111–e117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baselga J, Bradbury I, Eidtmann H, Di
Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van
Dooren V, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): A randomised, open-label, multicentre,
phase 3 trial. Lancet. 379:633–640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kolarova I, Vanasek J, Odrazka K, Melichar
B, Ryska A, Petera J, Vosmik M and Dolezel M: Therapeutic
significance of hormone receptor positivity in patients with HER-2
positive breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc
Czech Repub. 163:285–292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Collins DC, Cocchiglia S, Tibbitts P,
Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B,
Hill AD and Young LS: Growth factor receptor/steroid receptor cross
talk in trastuzumab-treated breast cancer. Oncogene. 34:525–530.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang YC, Morrison G, Gillihan R, Guo J,
Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, et
al: Different mechanisms for resistance to trastuzumab versus
lapatinib in HER2-positive breast cancers-role of estrogen receptor
and HER2 reactivation. Breast Cancer Res. 13:R1212011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cenciarini ME and Proietti CJ: Molecular
mechanisms underlying progesterone receptor action in breast
cancer: Insights into cell proliferation and stem cell regulation.
Steroids. 152:1085032019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Truong TH, Dwyer AR, Diep CH, Hu H, Hagen
KM and Lange CA: Phosphorylated progesterone receptor isoforms
mediate opposing stem cell and proliferative breast cancer cell
fates. Endocrinology. 160:430–446. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cervantes-Badillo MG, Paredes-Villa A,
Gómez-Romero V, Cervantes-Roldán R, Arias-Romero LE, Villamar-Cruz
O, González-Montiel M, Barrios-García T, Cabrera-Quintero AJ,
Rodríguez-Gómez G, et al: IFI27/ISG12 downregulates estrogen
receptor α transactivation by facilitating its interaction with
CRM1/XPO1 in breast cancer cells. Front Endocrinol (Lausanne).
11:5683752020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Durinck S, Spellman PT, Birney E and Huber
W: Mapping identifiers for the integration of genomic datasets with
the R/Bioconductor package biomaRt. Nat Protoc. 4:1184–1191. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
R Core Team, . R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2023
|
|
23
|
Győrffy B: Survival analysis across the
entire transcriptome identifies biomarkers with the highest
prognostic power in breast cancer. Comput Struct Biotechnol J.
19:4101–4109. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arpino G, Wiechmann L, Osborne CK and
Schiff R: Crosstalk between the estrogen receptor and the HER
tyrosine kinase receptor family: Molecular mechanism and clinical
implications for endocrine therapy resistance. Endocr Rev.
29:217–233. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dieci MV and Guarneri V: Should
triple-positive breast cancer be recognized as a distinct subtype?
Expert Rev Anticancer Ther. 20:1011–1014. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schedin TB, Borges VF and Shagisultanova
E: Overcoming therapeutic resistance of triple positive breast
cancer with CDK4/6 inhibition. Int J Breast Cancer.
2018:78350952018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sathyamoorthy N and Lange CA: Progesterone
and breast cancer: an NCI workshop report. Horm Cancer. 11:1–12.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hernández-Hernández OT and Camacho-Arroyo
I: Regulation of gene expression by progesterone in cancer cells:
Effects on cyclin D1, EGFR and VEGF. Mini Rev Med Chem. 13:635–642.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia W, Bacus S, Hegde P, Husain I, Strum
J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, et al: A model of
acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor
and a therapeutic strategy to prevent its onset in breast cancer.
Proc Natl Acad Sci USA. 103:7795–7800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kitowska K, Kowalska A, Mieszkowska M,
Piasecka D, Skladanowski AC, Romanska HM and Sadej R: Progesterone
impairs Herceptin effect on breast cancer cells. Oncol Lett.
15:1817–1822. 2018.PubMed/NCBI
|
|
31
|
Hyder SM, Liang Y, Wu J and Welbern V:
Regulation of thrombospondin-1 by natural and synthetic progestins
in human breast cancer cells. Endocr Relat Cancer. 16:809–817.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang Y, Wu J, Stancel GM and Hyder SM:
p53-dependent inhibition of progestin-induced VEGF expression in
human breast cancer cells. J Steroid Biochem Mol Biol. 93:173–182.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo LY, Grass L and Diamandis EP: Steroid
hormone regulation of the human kallikrein 10 (KLK10) gene in
cancer cell lines and functional characterization of the KLK10 gene
promoter. Clin Chim Acta. 337:115–126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mitre-Aguilar IB, Barrios-Garcia T,
Ruiz-Lopez VM, Cabrera-Quintero AJ, Mejia-Dominguez NR,
Ventura-Gallegos JL, Moreno-Mitre D, Aranda-Gutierrez A,
Mejia-Rangel J, Escalona-Guzman AR, et al: Glucocorticoid-dependent
expression of IAP participates in the protection against
TNF-mediated cytotoxicity in MCF7 cells. BMC Cancer. 19:3562019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gupta A, Mehta R, Alimirah F, Peng X,
Murillo G, Wiehle R and Mehta RG: Efficacy and mechanism of action
of Proellex, an antiprogestin in aromatase overexpressing and
Letrozole resistant T47D breast cancer cells. J Steroid Biochem Mol
Biol. 133:30–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nahta R, Takahashi T, Ueno NT, Hung MC and
Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab
resistance in breast cancer cells. Cancer Res. 64:3981–3986. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Glück S, Ross JS, Royce M, McKenna EF Jr,
Perou CM, Avisar E and Wu L: TP53 genomics predict higher clinical
and pathologic tumor response in operable early-stage breast cancer
treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer
Res Treat. 132:781–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Prat A, Bianchini G, Thomas M, Belousov A,
Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin
S, et al: Research-based PAM50 subtype predictor identifies higher
responses and improved survival outcomes in HER2-positive breast
cancer in the NOAH study. Clin Cancer Res. 20:511–521. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Ronde JJ, Rigaill G, Rottenberg S,
Rodenhuis S and Wessels LFA: Identifying subgroup markers in
heterogeneous populations. Nucleic Acids Res. 41:e2002013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brueffer C, Vallon-Christersson J, Grabau
D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl PO,
Manjer J, et al: Clinical value of RNA sequencing-based classifiers
for prediction of the five conventional breast cancer biomarkers: A
report from the population-based multicenter sweden cancerome
analysis network-breast initiative. JCO Precis Oncol.
2:PO.17.00135. 2018.PubMed/NCBI
|
|
41
|
Triulzi T, De Cecco L, Sandri M, Prat A,
Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari
A, et al: Whole-transcriptome analysis links trastuzumab
sensitivity of breast tumors to both HER2 dependence and immune
cell infiltration. Oncotarget. 6:28173–28182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Triulzi T, Regondi V, De Cecco L,
Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S,
Sfondrini L, Generali D and Tagliabue E: Early immune modulation by
single-agent trastuzumab as a marker of trastuzumab benefit. Br J
Cancer. 119:1487–1494. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Castagnoli L, Iezzi M, Ghedini GC,
Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P,
Campiglio M, Amici A, et al: Activated d16HER2 homodimers and SRC
kinase mediate optimal efficacy for trastuzumab. Cancer Res.
74:6248–6259. 2014. View Article : Google Scholar : PubMed/NCBI
|
